If your doctor recommends it, plan alcohol on days when you do not take medication injections
In MAESTRO-NASH, a phase III RCT recruiting 966 biopsy-proven MASLD patients with MASH and F2-F3 fibrosis, were randomized to three arms: placebo (n=321), resmetirom 80 mg (n=322) and resmetirom 100 mg (n=323), one pill per day
Understanding how glycine stacks up against these alternatives helps you evaluate which formulation best matches your needs
Common Side Effects (Both Oral and Injectable): Gastrointestinal Issues: These are the most common side effects for all GLP-1 medications: Nausea: Oral semaglutide (Rybelsus): 11-20% of patients Injectable semaglutide (Wegovy): 44% of patients Injectable tirzepatide (Zepbound): 30-37% of patients Why the difference: Lower bioavailability of oral medication means less systemic exposure, potentially resulting in fewer GI side effects
06 November 2025 A Correction to this paper has been published: References Volkow ND, Wang G-J, Tomasi D, Baler RD
Views expressed in the text are those of the authors and do not necessarily reflect the views of the publisher